Land: Singapore
Språk: engelska
Källa: HSA (Health Sciences Authority)
Nebivolol hydrochloride 5.45mg (equivalent to nebivolol)
A. MENARINI SINGAPORE PTE. LTD.
C07AB12
5mg
TABLET
Nebivolol hydrochloride 5.45mg (equivalent to nebivolol) 5mg
ORAL
Prescription Only
BERLIN-CHEMIE AG (granulation)
ACTIVE
2001-11-19
COMPOSITION One tablet contains: Active ingredients: nebivolol hydrochloride 5.45 mg (equal to 5 mg nebivolol). Excipients: Polysorbate 80, hypromellose, lactose monohydrate, maize starch, croscarmellose sodi- um, microcristalline cellulose, colloidal anhydrous silica, magnesium stearate PHARMACEUTICAL FORM Tablets. White, round, cross-scored tablets THERAPEUTIC CLASS Beta blocking agent, selective . PHARMACODYNAMIC PROPERTIES Nebivolol is a racemate of two enantiomers, SRRR-nebivolol (or d-nebivolol) and RSSS- nebivolol (or l-nebivolol). It combines two pharma- cological activities: • It is a competitive and selective beta-receptor antagonist: this effect is attributed to the SRRR- enatiomer (d-enantiomer). • It has mild vasodilating properties due to an interaction with the L-arginine/nitric oxide path- way. Single and repeated doses of nebivolol reduce heart rate and blood pressure at rest and during exercise, both in normotensive subjects and in hypertensive patients. The antihypertensive effect is maintained during chronic treatment. At therapeutic doses, nebivolol is devoid of alpha- adrenergic antagonism. During acute and chronic treatment with nebivolol in hypertensive patients systemic vascular resist- ance is decreased. Despite heart rate reduction, reduction in cardiac output during rest and exer- cise may be limited due to an increase in stroke volume. The clinical relevance of these haemody- namic differences as compared to other beta1 receptor antagonists has not been fully estab- lished. In hypertensive patients, nebivolol increases the NO-mediated vascular response to acetylcholine (ACh) which is reduced in patients with endothe- lial dysfunction. In a mortality–morbidity, placebo-controlled trial performed in 2128 patients ≥ 70 Läs hela dokumentet
NEBILET® Nebivolol COMPOSITION Each Nebilet tablet contains 5 mg of nebivolol (as nebivolol hydrochloride): 2.5 mg of SRRR-nebivolol (or d-nebivolol) and 2.5 mg of RSSS-nebivolol (or l-nebivolol). Excipients: Polysorbate 80, hypromellose, maize starch, croscarmellose sodium, microcristalline cellulose, colloidal anhydrous silica, magnesium stearate. Excipient with known effect: each tablet contains 141.75 mg of lactose monohydrate. PHARMACEUTICAL FORM Tablets. White, round, cross-scored tablets. The tablet can be divided in equal quarters. THERAPEUTIC CLASS Beta blocking agent, selective. PHARMACODYNAMIC PROPERTIES Pharmacotherapeutic group: Beta-blocking agent, selective. ATC code: C07AB12 Nebivolol is a racemate of two enantiomers, SRRR-nebivolol (or d-nebivolol) and RSSS-nebivolol (or l-nebivolol). It combines two pharmacological activities: • It is a competitive and selective beta-receptor antagonist: this effect is attributed to the SRRR-enantiomer (d-enantiomer). • It has mild vasodilating properties due to an interaction with the L-arginine/nitric oxide Pathway Single and repeated doses of nebivolol reduce heart rate and blood pressure at rest and during exercise, both in normotensive subjects and in hypertensive patients. The antihypertensive effect is maintained during the chronic treatment. At therapeutic doses, nebivolol is devoid of alphaadrenergic antagonism. During acute and chronic treatment with nebivolol in hypertensive patients systemic vascular resistance is decreased. Despite heart rate reduction, reduction in cardiac output during rest and exercise may be limited due to an increase in stroke volume. The clinical relevance of these haemodynamic differences as compared to other beta1 receptor antagonists has not been fully established. In hypertensive patients, nebivolol increases the NO-mediated vascular response to acetylcholine (ACh) which is reduced in patients with endothelial dysfunction. In a mortality–morbidity, placebo-controlled trial performed in 2128 patients ≥ 70 years (me Läs hela dokumentet